The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Mengzhao Wang
No Relationships to Disclose
 
Paul Mitchell
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Weiqi Nian
No Relationships to Disclose
 
Chao-Hua Chiu
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Novartis; Roche
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharmaceutical Group Co. Ltd
Research Funding - Hansoh Pharmaceutical Group Co. Ltd (Inst)
 
Yanqiu Zhao
No Relationships to Disclose
 
Wu-Chou Su
No Relationships to Disclose
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anchiano; Apollomics; AstraZeneca; bio-thera; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Inivata (Inst); Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seattle Genetics; takeda; Turning Point Therapeutics
Research Funding - Takeda
 
Tsung-Ying Yang
No Relationships to Disclose
 
Viola Weijia Zhu
Stock and Other Ownership Interests - TP Therapeutics; TP Therapeutics (I)
Honoraria - AstraZeneca; Blueprint Medicines; Roche/Genentech; Takeda; Xcovery
Consulting or Advisory Role - AstraZeneca; Roche/Genentech; Takeda; TP Therapeutics; Xcovery
Speakers' Bureau - AstraZeneca; Blueprint Medicines; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech; Takeda; TP Therapeutics
 
Michael Millward
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Dizal Pharma (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MaxiNovel (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Therapim (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Yun Fan
No Relationships to Disclose
 
Wen Tsung Huang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Liyan Jiang
No Relationships to Disclose
 
Li Zheng
Employment - Dizal Pharma
Stock and Other Ownership Interests - Dizal Pharma
Honoraria - Dizal Pharma
Travel, Accommodations, Expenses - Dizal Pharma
 
Xiuhui Ye
Employment - Dizal Pharma
Stock and Other Ownership Interests - Dizal Pharma
Travel, Accommodations, Expenses - Dizal Pharma
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo Oncology
Consulting or Advisory Role - Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Takeda; Voronoi
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention